Systematically analyze the registration information of the clinical research program of Chinese patent medicine for the treatment of new coronavirus pneumonia in order to improve the quality of relevant clinical research design and provide references and suggestions for the evaluation of Chinese patent medicine after marketing.Searched the website of the Chinese Clinical Trial Registry (www.chictr.org.cn) and the website of the American Clinical Trial Registry (clinicaltrials.gov), searched for new pneumonia, COVID-19, etc. as search terms, and searched for new Chinese medicines for new coronary virus pneumonia Related clinical research protocols.Screen clinical studies according to the exclusion criteria, and extract data such as registration number, study title, study design and type, interventions, study population, sample size, course of treatment, and main efficacy indicators, and use descriptive analysis to analyze the registration information of included studies analysis. A total of 35 research programs related to new-type coronavirus pneumonia and proprietary Chinese medicines were included. The research units were mainly Hubei, Beijing, Guangdong, and Zhejiang, and the research implementation units were mainly based in Hubei, Guangdong, and Zhejiang regional hospitals. The study design types are mainly interventional studies, with a total of 34 registrations, of which 29 are randomized studies, 4 are non-randomized controlled trials, 1 is consecutively included, and includes 1 observational study. Study design Is a non-randomized controlled trial.The 8 proprietary Chinese medicines involved in the 35 studies are the drugs recommended in the new coronary pneumonia diagnosis and treatment plan (seventh edition), and a total of 16 clinical trial research plans have been registered. Interventions evaluated include Chinese patent medicines (Xiyanping injection, Lianhua Qingwen capsules / granules, compound Houttuynia cordata mixture, Xuebijing injection, Tanreqing injection / capsule, Shuanghuanglian oral solution, antiviral particles / Oral solution, Liushen capsule, Babaodan, Huoxiangzhengqi oral solution / drop pill, Shenfu injection, Shenqi Fuzheng injection, Jinye Baidu granule, Shufengjiedu capsule, Reduning injection, cough Shuangqing Capsule, Honeysuckle Oral Liquid, Jingyin Granules, Kesu Stop Syrup, Keqing Capsule, Huaier Granules, Pediatric Huatan Zhike Granules).The main efficacy indicators were antipyretic time, disease recovery time, negative rate of new crown virus nucleic acid negative rate, body temperature normalization time, pneumonia inflammation index, and TCM symptom score. The results show that the clinical research on the treatment of neo-pneumocoronary pneumonia with Chinese patent medicines has responded quickly, and many clinical studies have been registered, including the entire process of disease diagnosis and treatment and prevention. However, there are still some problems, such as unclear research population, representative evaluation indicators, etc. The design and implementation of related studies need to be optimized to further improve the feasibility of clinical trial research. I hope that it can be used for more clinical research The program provides a reference.